Abstracts tagged "gout"

Abstract Number: 2341 • 2015 ACR/ARHP Annual Meeting
Treatment of Gout with Pharmacological Vs. Non-Pharmacological Complementary Therapy in the U.S.: An Internet Survey
Jasvinder A. Singh¹, Nipam Shah², N. Lawrence Edwards³ and H. Ralph Schumacher Jr.⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University fo Alabama at Birmingham, Birmingham, AL, ³University of Florida, Gainsville, FL, ⁴Medicine, Rheumatology, U Penn & VA Med Ctr, Philadelphia, PA
Background/Purpose: The interplay of use of dietary supplement, diet modification and ULT adherence in gout management is not known. Therefore, we aimed to begin to…
Abstract Number: 102 • 2015 ACR/ARHP Annual Meeting
Xanthine Oxidase Gene Variants and Their Association with Blood Pressure and Incident Hypertension: A Population Based Study
Lieke E.J.M. Scheepers¹, Jan A. Staessen^2,3, Lutgarde Thijs², Erika Salvi⁴, Annelies Boonen⁵ and Ilja C.W. Arts⁶, ¹Department of Internal Medicine, Division of Rheumatology, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre, Maastricht, Netherlands, ²Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology KU Leuven, Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium, ³R & D Group VitaK, Maastricht University, Maastricht, Netherlands, ⁴Department of Health Sciences, University of Milan, Milan, Italy, ⁵Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁶Department of Epidemiology, CAPHRI School for Public Health and Primary Care, CARIM School for Cardiovascular Diseases, and MaCSBio Maastricht Centre for Systems Biology, Maastricht University, Maastricht, Netherlands
Background/Purpose: Uric acid (UA) has been associated with blood pressure (BP) and hypertension. During the final stage of purine metabolism, xanthine oxidoreductase (XOR) breaks down…
Abstract Number: 1359 • 2015 ACR/ARHP Annual Meeting
Risk Factors for the Development of Gout in HIV Patients: A Retrospective Study
Bibi Ayesha, Rafeeq Ahmed, Richard Peralta, Syed Bokhari, Anupama Menon, Giovanni Franchin and Sridhar Chilimuri, Medicine, Bronx Lebanon Hospital Center, Bronx, NY
Background/Purpose: The interaction between human immunodeficiency virus (HIV) disease and rheumatic disorders has been described as “an unfortunate experiment of nature” that could provide insights…
Abstract Number: 2342 • 2015 ACR/ARHP Annual Meeting
Uric Acid-Lowering Therapy Management Among Rural Veterans Affairs Primary Care Providers
Michael Darley¹, Grant W. Cannon² and Christopher Jackson³, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: ACR guidelines exist for the management of gout including the use of uric acid-lowering therapy. ACR guidelines recommend routine monitoring of uric acid levels…
Abstract Number: 220 • 2015 ACR/ARHP Annual Meeting
A Genome-Wide Association Study Reveals Association of the Transferrin Receptor Locus with Gout
Tony R. Merriman¹, Murray Cadzow², Callum Tanner², Matthew A. Brown³, Katie Cremin⁴, Matthijs Janssen⁵, Tim Jansen⁶, Leo A. Joosten⁷, Timothy Radstake⁸, Philip L. Riches⁹, Anne-Kathrin Tausche¹⁰, Frederic Lioté¹¹, Alex So^12,13, Andre M. van Rij², Gregory T. Jones¹⁴, Lisa K. Stamp¹⁵, Nicola Dalbeth¹⁶ and Cushla McKinney², ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³The University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Diamantina Institute, University of Queensland, Brisbane, Australia, ⁵Rheumatology Dept, Ziekenhuis Rijnstate, Arnhem, Netherlands, ⁶P O Box 581, Haarlem, Netherlands, ⁷Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁸Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁹Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom, ¹⁰Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ¹¹Rheumatology Department; Inserm UMR-S606; Paris-Diderot University, hôpital Lariboisiere, Paris, France, ¹²Service De Rhumatologie, CHUV, Lausanne, Switzerland, ¹³Department of Rheumatology, CHUV, Lausanne, Switzerland, ¹⁴Surgery, University of Otago, Dunedin, New Zealand, ¹⁵Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ¹⁶Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Acute gouty arthritis results from an innate immune response to monosodium urate (MSU) crystals deposited in the joints and soft tissues of hyperuricaemic individuals.…
Abstract Number: 2027 • 2015 ACR/ARHP Annual Meeting
Development of a Dual Energy Computed Tomography Scoring System for Measurement of Urate Deposition in Gout
Sara Bayat¹, Opetaia Aati², Juergen Rech¹, Alexander Cavallaro³, Michael Lell³, Elizabeth Araujo⁴, Christina Petsch⁴, Lisa K. Stamp⁵, Georg A. Schett⁶, Bernhard Manger¹ and Nicola Dalbeth², ¹Department of Internal Medicine 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Department of Radiology, University of Erlangen-Nuremberg, Department of Radiology, Erlangen, Germany, ⁴Medical Department 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ⁶University of Erlangen-Nuremberg, Erlangen, Germany
Development of a Dual Energy Computed Tomography Scoring System for Measurement of Urate Deposition in Gout Background/Purpose: Dual energy computed tomography (DECT) can visualize urate…
Abstract Number: 2349 • 2015 ACR/ARHP Annual Meeting
The Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients with Severe Renal Impairment
Ji Seon Oh and Seungwon Choi, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea
Background/Purpose: Febuxostat has shown to be effective and safe in the treatment of hyperuricemia in patients with mild-to-moderate renal impairment without dose adjustment. However, there…
Abstract Number: 221 • 2015 ACR/ARHP Annual Meeting
Clinical and Genetic Characteristics of Diuretic-Associated Gout: A Case-Control Study
Sirisha Mitnala¹, Amanda Phipps-Green², Christopher Franklin¹, Anne Horne³, Lisa K. Stamp⁴, Tony R. Merriman⁵ and Nicola Dalbeth^1,3, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Department of Medicine, University of Auckland, Auckland, New Zealand, ⁴Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ⁵Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Hyperuricaemia and secondary gout are well-recognised complications of diuretic use. Variants in ABCG2 and SLC2A9 have been identified as the two major genetic risk…
Abstract Number: 2095 • 2015 ACR/ARHP Annual Meeting
Dietary Patterns (DASH, Prudent, Western Diets) and the Risk of Gout in US Women – the Nurses Health Study
Jeewoong Choi¹, Na Lu², Yuqing Zhang³, Sharan K. Rai⁴, Gary C. Curhan⁵ and Hyon K. Choi², ¹Massachusetts College of Pharmacy and Health Sciences, Boston, MA, ²Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³BUSM, Boston, MA, ⁴Experimental Medicine, University of British Columbia, Vancouver, BC, Canada, ⁵Renal Division, Brigham and Women's Hospital, Boston, MA
Background/Purpose: There is a remarkable, rising disease burden of gout and associated cardiovascular-metabolic comorbidities (e.g., hypertension in 74% and obesity in 53% of cases in…
Abstract Number: 2351 • 2015 ACR/ARHP Annual Meeting
A Study to Evaluate the Pharmacodynamics, Pharmacokinetics and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout
Alexandra Steinberg, Yun-Jung Choi, Robert Martin, Charles McWherter and Pol Boudes, Cymabay Therapeutics, Newark, CA
Background/Purpose: Arhalofenate is a novel Urate-Lowering Anti-Flare Therapy (ULAFT) for the treatment of gout. It lowers serum uric acid (sUA) by blocking URAT1, a tubular…
Abstract Number: 223 • 2015 ACR/ARHP Annual Meeting
Increased Platelet Reactivity in Gout: A Potential Mechanism for Adverse Cardiovascular Events
Richard Conway¹, Claire-Louise Murphy², Anne Madigan², Patricia Kavanagh², Liz Geraghty², Laura Helbert², Kelly Stephens³, John J. Carey⁴, Eimear Dunne⁵, Dermot Kenny⁵ and Geraldine M. McCarthy⁶, ¹Rheumatology, Mater Misericordiae University Hospital, Dublin 2, Ireland, ²Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ³Mater Misericordiae University Hospital, Clinical Research Center, Dublin, Ireland, ⁴Rheumatology, Galway University Hospitals, Galway, Ireland, ⁵Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ⁶University College Dublin, Dublin, Ireland
Background/Purpose: Patients with inflammatory arthritis, including gout, have an increased risk of cardiovascular events and mortality. Increased platelet reactivity is a risk marker for cardiovascular…
Abstract Number: 2099 • 2015 ACR/ARHP Annual Meeting
Genome-Wide Association Study of Clinically-Defined Gout Identifies Multiple Risk Loci: A Clue for Future Companion Diagnostics of Gout
Hirotaka Matsuo¹, Ken Yamamoto², Hirofumi Nakaoka³, Akiyoshi Nakayama¹, Masayuki Sakiyama¹, Atsushi Takahashi^4,5, Takahiro Nakamura⁶, Yusuke Kawamura¹, Nobuyuki Hamajima⁷, Ituro Inoue⁸, Michiaki Kubo⁴, Kimiyoshi Ichida⁹, Hiroshi Ooyama¹⁰, Toru Shimizu¹¹ and Nariyoshi Shinomiya¹, ¹Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical College, Tokorozawa, Japan, ²Department of Medical Chemistry, Kurume University School of Medicine, Kurume, Japan, ³Division of Human Genetics, Department of Integrated Genetics, National Institute of Genetics, Mishima, Japan, ⁴Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ⁵Research Center, National Cerebral and Cardiovascular Center, Suita, Japan, ⁶National Defense Medical College, Laboratory for Mathematics, Tokorozawa, Japan, ⁷Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁸Department of Integrated Genetics, National Institute of Genetics, Mishima, Japan, ⁹Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan, ¹⁰Ryougoku East Gate Clinic, Tokyo, Japan, ¹¹Midorigaoka Hospital, Takatsuki, Japan
Background/Purpose: Gout, caused by hyperuricaemia, is a multifactorial disease. Recently, genome-wide association studies (GWASs) of gout have been reported; however, they included self-reported gout cases.…
Abstract Number: 2352 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety in Patients with Tophaceous Gout Receiving Lesinurad and Febuxostat Combination Therapy: Interim Analysis of an Extension Study
Nicola Dalbeth¹, Graeme Jones², Robert Terkeltaub³, Dinesh Khanna⁴, Jeff Kopicko⁵, Scott Adler⁶, Nihar Bhakta⁵, Maple Fung⁵, Chris Storgard⁵, Scott Baumgartner⁵ and Fernando Perez-Ruiz⁷, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶AstraZeneca Pharmaceuticals, Wilmington, DE, ⁷Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: In the randomized, double-blind, placebo-controlled, Phase III CRYSTAL trial, more patients taking lesinurad 200 mg (LESU200) or 400 mg (LESU400), in combination with febuxostat…
Abstract Number: 226 • 2015 ACR/ARHP Annual Meeting
Prevalence of Cardiovascular Disease in Patients with Gout, Osteoarthritis or Both
Daisy Bang¹, Jinfeng Xu², Robert T. Keenan³, Virginia Pike¹, Aaron Lehmann¹, Craig T. Tenner⁴, Daria Crittenden¹, Michael H. Pillinger¹ and Svetlana Krasnokutsky¹, ¹Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ²Biostatistics, New York University School of Medicine, New York, NY, ³Rheumatology, Duke University, Durham, NC, ⁴Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Osteoarthritis (OA) and gout are each associated with increased cardiovascular disease (CVD), but their relative impacts on CV risk are not known. We compared…
Abstract Number: 2108 • 2015 ACR/ARHP Annual Meeting
A Pragmatic Cluster-Randomized Controlled Trial of an Automated, Pharmacy-Based Intervention to Optimize Allopurinol Therapy in Gout
Ted R. Mikuls¹, T C Cheetham², Nazia Rashid², Gerald D. Levy³, Artak Kerimian⁴, KJ Low², Brian Coburn⁵, David T. Redden⁶, S. Louis Bridges Jr.⁷, Kenneth G. Saag⁶ and Jeffrey R. Curtis⁷, ¹Medicine, University of Nebraska Medical Center, Omaha, NE, ²Pharmacy Analytical Services, Kaiser Permanente Southern California, Downey, CA, ³Rheumatology, Kaiser Permanente Southern California, Downey, CA, ⁴Ambulatory Care Pharmacy, Kaiser Permanente Southern California, Downey, CA, ⁵Internal Medicine - Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout is a common form of inflammatory arthritis, often treated with allopurinol as a first-line urate lowering therapy. We have designed a large…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].